Articles

O.13 Colchicine as salvage for refractory pyrexia due to BRAF and MEK inhibitors: a case report

BJMO - 2021, issue 3, march 2021

Michael Saerens , Ingeborg Hilderson , Anne Hoorens , Celine Jacobs

Introduction: Pyrexia is a frequent complication of treatment with BRAF and MEK inhibitors. Management includes a full infectious workup, initiation of paracetamol, NSAIDs, dose interruption and steroids. In rare cases pyrexia is refractory to classic management. Pathogenesis of pyrexia shows similarities with familial mediteranian fever, a disease that usually responds well to colchicine.

Read more
X